Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Must be hard to keep all your different accounts straight allo...
This is my favorite board to observe science deniers discussing stem cells.
"I don't think science knows" - Trump
I prefer to get my facts from reality TV stars instead of scientist too allo
Also, Jaime is correct, we know that at least 45 events have occurred, possibly more.
"The interim readout will be conducted based on a minimum of 45 events, which have already occurred."
https://finance.yahoo.com/news/pluristem-ceo-issues-shareholder-clinical-111010726.html
Right, ARKG fund has more than doubled their holdings since 04/08.
ARKG Holdings as of 04/08 = 670,215
Yesterday's holdings = 1,353,347
1,353,347 - 670,215 = 683,132
https://ark-funds.com/wp-content/fundsiteliterature/holdings/ARK_GENOMIC_REVOLUTION_MULTISECTOR_ETF_ARKG_HOLDINGS.pdf
ARKG holdings as of 04/08/20: 670,215 shares
683,132 shares purchased between 04/08 and yesterday.
You are correct, the numbers do not lie.
Still researching but it appears NICE (National Institute for Health and Care Excellence) can, based on technology appraisals, recommend the use of PLX-PAD through the NHS.
NICE - https://en.wikipedia.org/wiki/National_Institute_for_Health_and_Care_Excellence
NHS - https://en.wikipedia.org/wiki/National_Health_Service
"Technology appraisals and the NHS Constitution
The NHS is legally obliged to fund and resource medicines and treatments recommended by NICE's technology appraisals.
The NHS Constitution states that patients have the right to drugs and treatments that have been recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.
When NICE recommends a treatment 'as an option', the NHS must make sure it is available within 3 months (unless otherwise specified) of its date of publication. This means that, if a patient has a disease or condition and the doctor responsible for their care thinks that the technology is the right treatment, it should be available for use, in line with NICE's recommendations."
- https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance
https://www.sps.nhs.uk/medicines/emiplacel/
"Apr 20 · Emiplacel has been prioritised for potential TA guidance production. Topic has been passed to scoping team to prepare for a consultation exercise [16]."
https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance
I always take my science advise from science deniers, thanks clown
You have been saying this for years and we all thought you were crazy. Well done Allo.
You are referring to Nikko and Sumitomo?
Can you share the other two funds besides ARK Investment, LLC and ARKG? Thanks.
Yes, that we know of. I haven't been able to find much info on Clover Wolf Capital who recently purchased 1,092,057 shares. We also do not know the two institutions that bought the entirety of the recent $15 million offering.
ARKG holdings as of 04/08/20: 670,215 shares
ARKG holdings as of 4/24/20: 734,601 shares
ARKG holdings as of 5/11/20: 811,057 shares
https://ark-funds.com/wp-content/fundsiteliterature/holdings/ARK_GENOMIC_REVOLUTION_MULTISECTOR_ETF_ARKG_HOLDINGS.pdf
I guess that's why they're trying to raise another $100M
MESO has approved products and revenue. I agree PSTI is significantly undervalued though.
Thank you SuperSquirrel.
FYI - if you turn on the subtitles/closed caption and click on settings - you can change the subtitles to English. Translation is not good but gives you an idea of what they are saying.
The manufacturing facility at min 1:55 looks like what we need for mass production!
How are you interpreting the "Total cost (Approximate amount)"? Thanks.
https://www.eib.org/en/projects/pipelines/all/20190880
Do you have a link to the full presentation? Thanks.
University took 1 day to get compassionate use approval, same as PSTI with the NJ case. Actual clinical trial approval takes considerably longer.
Feels good to be green again, hope you get there soon.
At what share price will you claim you always knew the company was going to be successful? Probably north of $20?
Is it dropping? :)
Good spot
This picture looks familiar: https://www.kenup.eu/news#&gid=1577129481&pid=5
"In the last few months, we have been holding discussions with the FDA and EMA in order to confirm and agree on the changes in the parameters and final protocol design of the interim analysis of the CLI clinical data, which may lead to conditional marketing approval in Europe. I expect to be able to update you on those understandings in the coming weeks."
https://finance.yahoo.com/news/pluristem-provides-covid-19-preparedness-120010593.html
Congrats to all longs
Goodbye little Scotty - good luck to you
Poor Scotty, you really don't know
Speaking of looking stupid - Scotty has 2,600+ posts where you can bear witness of being wrong for years
Exactly - 2,500+ posts and they are all short sighted and unintelligent
What would he/she do with their life if not post the same thing every day for years? I guess look like a fool now...
Midas - you know this is not in reference to PSTI, ATHX or MESO.
Nope, that's not what I read auto.
Just an error in google translate
Get a life
Correct, phase III comparing PLX-R18 with the "current standard of care".
"We have submitted a proposal to the Biomedical Advanced Research and Development Authority (BARDA)that is strategically designed to demonstrate the superiority of PLX-R18 versus current standards of care."
https://www.pluristem.com/wp-content/uploads/2019/11/PSTI_CEO_Letter_Nov_2019_FINAL_isa.pdf